Protocol List

The Protocol List provides a listing of NCI clinical trials that are supported by the CTSU and are either active, near activation or temporarily closed. The list may be sorted by Protocol Number, Lead Organization, NIH Program, Status, or Phase. Clicking to the right of each title in the header row will display an arrow, an upwards facing arrow will sort by ascending order and a downwards facing arrow will display by descending order. Each protocol number is hyperlinked and clicking on the protocol number will open a new website, the National Cancer Institute’s Clinical Trials Physicians Data Query (PDQ®). PDQ provides additional information about each clinical trial including the trial summary, eligibility criteria and a listing of sites that have the trial open. The protocol list can be exported to and Excel or CSV file or printed by selecting the icon located above the header row.

*Some accruals have occurred outside of the CTSU systems and are collected manually, thus the total accrual number may not be accurate.
#Protocol NumberLead OrganizationNIH ProgramDiseaseStatusProtocol TitlePhaseAccrual TargetAccrual Total
  • First Page
  • Previous Page
  • Page 1 of 6
  • Next Page
  • Last Page
  • Last update: 10:40:31 PM UTC
1EAY131-S2ECOG-ACRINNCTNN/AActiveMATCH Treatment Subprotocol S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 Mutations00
2EAY131-Z1HECOG-ACRINNCTNN/AActiveMATCH Treatment Subprotocol Z1H: Phase II Study of Copanlisib in Patients with Tumors with Deleterious PTEN Sequencing Result and PTEN Expression by IHC00
3EAY131-Z1IECOG-ACRINNCTNN/ATemporarily Closed to AccrualMATCH Treatment Subprotocol Z1I: Phase II Study of AZD1775 in Patients with Tumors Containing BRCA1 and BRCA2 Mutations00
4PBTC-049PBTCMISCELLANEOUSCNS Cancer (Primary tumor)ActiveA Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Primary CNS TumorsI360
5PBTC-051PBTCMISCELLANEOUSCNS Cancer (Primary tumor)ActivePhase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem GliomaI456
6URCC-16092URCCNCORPGastrointestinal CancerActivePhase II Study of Low-Dose Ibuprofen for Cognitive Impairment in Colorectal Cancer Patients Receiving ChemotherapyII860
7WF-20817CDWAKENCORPLung, Mediastinal, and Pleural CancerActiveImplementation of Smoking Cessation Services within NCI NCORP Community Sites with Organized Lung Cancer Screening ProgramsOther11140
8EAY131-K1ECOG-ACRINNCTNN/AActiveMATCH Treatment Subprotocol K1: Phase II Study of Erdafitinib (JNJ-42756493) in Patients with Tumors with FGFR Amplifications00
9EAY131-K2ECOG-ACRINNCTNN/AActiveMATCH Treatment Subprotocol K2: Phase II Study of Erdafitinib (JNJ-42756493) in Patients with Tumors with FGFR Mutations and Fusions00
10EAY131-C2ECOG-ACRINNCTNN/AActiveMATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion00
11A061402ALLIANCENCTNMyelomaActiveSolitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation TherapyIII11011
12S1605SWOGNCTNUrothelial/ Bladder CancerActivePhase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder CancerII14899
139903LAO-MA036ETCTNLung, Mediastinal, and Pleural CancerActiveA Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase InhibitorI5021
14EA5142ECOG-ACRINNCTNLung, Mediastinal, and Pleural CancerActiveAdjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung CancersIII714567
15NRG-GI002NRGNCTNGastrointestinal CancerActiveA Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal CancerII348214
16S1418SWOGNCTNBreast CancerActiveA Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant ChemotherapyIII1000303
17A011502ALLIANCENCTNBreast CancerActiveA Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC TrialIII2936860
1810020LAO-CT018ETCTNBreast CancerActiveA Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast CancerII9014
199948LAO-MN026ETCTNFemale Reproductive System CancerActivePhase 1 Dose Escalation and Randomized Phase 2 Trial of Carboplatin and Gemcitabine with or without M6620 (VX-970) in First Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube CancerI/II246
209775LAO-MN026ETCTNLeukemiaTemporarily Closed to AccrualA Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)II3516
21S1512SWOGNCTNSkin CancerActive A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)II7717
229910LAO-11030ETCTNLung, Mediastinal, and Pleural CancerActiveA Phase 1 Trial of MLN0128 (TAK-228) in Combination with Osimertinib (AZD9291) in Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) After Progression on a Previous EGFR Tyrosine Kinase InhibitorI3612
23EA8143ECOG-ACRINNCTNKidney CancerActiveA Phase 3 RandOmized Study Comparing PERioperative Nivolumab Vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)III766120
249979LAO-MN026ETCTNMiscellaneous and Metastatic CancerTemporarily Closed to AccrualPhase 1 and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2-Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain MetastasesI475
259767LAO-CT018ETCTNUrothelial/ Bladder CancerActiveAn Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 MutationII20911
269984LAO-CT018ETCTNMale Reproductive System CancerActiveA Randomized Phase 2 Study of Cediranib in Combination with Olaparib Versus Olaparib Alone in Men with Metastatic Castration Resistant Prostate CancerII9086
27A221502ALLIANCENCORPLung, Mediastinal, and Pleural CancerActivePulmonary Rehabilitation Before Lung Cancer ResectionIII1949
2810005LAO-NCIETCTNSoft Tissue Cancer/SarcomaActiveA Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part SarcomaII2623
2910031LAO-MA036ETCTNBreast Cancer;Female Reproductive System Cancer;Miscellaneous and Metastatic CancerActiveA Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors with Expansion in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast CancerI4016
30S1616SWOGNCTNSkin CancerActiveA Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 AgentII9426
31EAF151ECOG-ACRINNCTNCNS Cancer (Primary tumor)ActiveChange in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent GlioblastomaII16524
3210013LAO-NC010ETCTNBreast CancerTemporarily Closed to AccrualRandomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, with or Without Atezolizumab in Triple Negative Breast Cancer (TNBC)II6060
33EA8134ECOG-ACRINNCTNMale Reproductive System CancerActiveInPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)III2008
34NRG-GI003NRGNCTNGastrointestinal CancerActiveA Phase III Randomized Trial of Protons Versus Photons for Hepatocellular CarcinomaIII16721
3510026LAO-MA036ETCTNLeukemiaActiveA Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid LeukemiaI4818
36NRG-BR005NRGNCTNBreast CancerActiveA Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without SurgeryII17571
37EA1151ECOG-ACRINNCORPBreast CancerActiveTomosynthesis Mammographic Imaging Screening Trial (TMIST)III1649465686
389974LAO-MA036ETCTNLung, Mediastinal, and Pleural CancerTemporarily Closed to AccrualA Phase II Study of Olaparib Plus Cediranib in Combination with Standard Therapy for Small Cell Lung CancerII1329
3910009LAO-CT018ETCTNLeukemiaActiveA Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination with the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients with Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy FailureI277
4010042LAO-CT018ETCTNLung, Mediastinal, and Pleural CancerActiveA Phase II Trial of AZD9291 (Osimertinib) with or without Bevacizumab in Patients with EGFR Mutation Positive NSCLC and Brain MetastasesII982
4110030LAO-MD017ETCTNLeukemiaActiveA Phase 1 Study of Blinatumomab in Combination with Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients with Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic LeukemiaI308
4210015EDDO-MI014MISCELLANEOUSSoft Tissue Cancer/SarcomaTemporarily Closed to AccrualA Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid HemangioendotheliomaII2929
4310021LAO-MA036ETCTNGastrointestinal Cancer;Lung, Mediastinal, and Pleural CancerActiveA Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic Colorectal and NSCLCII18088
44NRG-GY009NRGNCTNFemale Reproductive System CancerActiveA Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian CancerII/III488141
45EAY131-JECOG-ACRINNCTNN/AActiveMATCH Treatment Subprotocol J; Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers, and Non-Colorectal Cancers with HER2 Amplification00
46A041501ALLIANCENCTNLeukemiaActiveA Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALLIII32417
47NRG-LU002NRGNCTNLung, Mediastinal, and Pleural CancerActiveMaintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III TrialII/III40021
48ADVL1622COGNCTNBone Cancer;Endocrine Cancer;Gastrointestinal Cancer;Kidney Cancer;Miscellaneous and Metastatic Cancer;Soft Tissue Cancer/SarcomaActivePhase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare TumorsII14686
49AALL15P1COGNCTNLeukemiaTemporarily Closed to AccrualA Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene RearrangementII11658
50A191402CDALLIANCENCORPMale Reproductive System CancerActiveTesting Decision Aids to Improve Prostate Cancer Decisions for Minority MenIII172131